Apart from that, to overcome the inhibitory effects of the TME, using ICI for blocking PD-1 and administering adenosine A2BR agonist BAY 60-6583 with CAR-T has demonstrated efficacy in preclinical and clinical studies by preventing exhaustion and improving anti-tumor effect [370]. This evidence concerns the gene PDCD1 and neoplasm.